Immatics (IMTX) Total Non-Current Liabilities (2019 - 2026)
Immatics (IMTX) posted Total Non-Current Liabilities of $41.0 million for Q4 2025, down 11.47% sequentially from $46.3 million in Q3 2025, and down 28.03% YoY from $57.0 million in Q4 2024.
Analysis
Immatics (IMTX) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Immatics has reported Total Non-Current Liabilities for 7 years, with the latest figure at $41.0 million in Q4 2025.
- Quarterly Total Non-Current Liabilities fell 28.03% year-over-year to $41.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $41.0 million (down 28.03% YoY) and the FY2025 annual result came in at $39.8 million, down 31.03% from the prior year.
- Total Non-Current Liabilities fell to $41.0 million in Q4 2025 per IMTX's latest filing, from $46.3 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $146.1 million in Q4 2023 and troughed at $41.0 million in Q4 2025.
- A 5-year average of $83.3 million and a median of $78.3 million in 2021 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities surged 76.84% in 2022, then plunged 61.01% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $63.4 million in 2021, then surged by 57.69% to $100.0 million in 2022, then surged by 46.11% to $146.1 million in 2023, then plunged by 61.01% to $57.0 million in 2024, then declined by 28.03% to $41.0 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $41.0 million, $46.3 million, and $51.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | 33.89 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.89 Mn |
| Mar 31, 2026 | 37.71 Mn |
| Dec 31, 2025 | 41.00 Mn |
| Sep 30, 2025 | 46.32 Mn |
| Jun 30, 2025 | 51.48 Mn |
| Mar 31, 2025 | 51.87 Mn |
| Dec 31, 2024 | 56.97 Mn |
| Sep 30, 2024 | 75.95 Mn |
| Jun 30, 2024 | 103.55 Mn |
| Mar 31, 2024 | 119.38 Mn |
| Dec 31, 2023 | 146.11 Mn |
| Sep 30, 2023 | 74.62 Mn |
| Jun 30, 2023 | 73.69 Mn |
| Mar 31, 2023 | 83.53 Mn |
| Dec 31, 2022 | 100.00 Mn |
| Sep 30, 2022 | 118.10 Mn |
| Jun 30, 2022 | 138.04 Mn |
| Mar 31, 2022 | 83.44 Mn |
| Dec 31, 2021 | 63.42 Mn |
| Sep 30, 2021 | 66.78 Mn |